Synapse - Works

Results (5377)

Disparities in incidence and mortality of hematologic cancers in Southeast Asia: A 2020 analysis

Meeting Abstract

Feliciano, E. J. G.; Jain, U.; Dee, E. C. C.; Jain, B.; Patel, T. A.; Selokar, A.; Eala, M. A.; Ting, F. I. L.; Gin, G. G.; Pathy, N. B.
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

A phase 2, open-label, single-arm, prospective, multicenter study of nab-sirolimus plus letrozole in advanced or recurrent endometrioid endometrial cancer

Meeting Abstract

Dockery, L. E.; Slomovitz, B. M.; Musa, F.; Mathews, C. A.; Priebe, A. M.; Green, A.; Puechl, A.; Birrer, M. J.; Spirtos, N. M.; Ding, L.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Patient characteristics associated with primary prophylactic granulocyte colony-stimulating factor (G-CSF) use among women treated for early-stage breast cancer

Meeting Abstract

Gallagher, G. B.; O'Connell, K.; Bhimani, J.; Blinder, V. S.; Burganowski, R. P.; Griggs, J. J.; Kolevska, T.; Kroenke, C.; Laurent, C.; Liu, R.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

A phase 2 study of neoadjuvant PARP inhibition followed by radical prostatectomy (RP) in patients with unfavorable intermediate-risk or high-risk prostate cancer with BRCA1/2 gene alterations (NePtune)

Meeting Abstract

McKay, R. R.; Liu, L.; Pu, M.; Araneta, A.; Yuen, K. L.; Gomez, J.; Castano, N.; Ajmera, A.; Ye, H.; Pili, R.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Epcoritamab + R-DHAX/C in transplant-eligible patients (pts) with high-risk relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)

Meeting Abstract

Karimi, Y.; Abrisqueta, P.; de Vos, S.; Nijland, M.; Offner, F.; Osei-Bonsu, K.; Rana, A.; Archer, K. G.; Song, Y.; Cordoba, R.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

A phase 1/2 study to investigate the safety and efficacy of OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced solid tumors

Meeting Abstract

Schoenfeld, A. J.; Warner, A. B.; Chesney, J. A.; Thomas, S. S.; Hamid, O.; In, G. K.; Shoushtari, A. N.; Samhouri, Y.; Hari, P. N.; Ramsingh, G.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in JAKi-naive myelofibrosis

Meeting Abstract

Mascarenhas, J.; Maher, K. R.; Rampal, R.; Bose, P.; Podoltsev, N. A.; Hong, J.; Wang, X.; Kye, S.; Harrison, C.
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

CLARITY-PanTumor01: A phase 2 trial of the claudin 18.2-specific antibody-drug conjugate AZD0901 (CMG901) in patients with CLDN18.2-expressing advanced solid tumors

Meeting Abstract

Raufi, A. G.; Goyal, L.; Smyth, E.; Szekeres, P.; Petrone, M.; Hobson, R.; Thress, K.; Origuchi, M.; Nehra, J.; Brown, J. S.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Emavusertib (CA-4948) in combination with ibrutinib in patients with relapsed/refractory primary central nervous system lymphoma (R/R PCNSL)

Meeting Abstract

Grommes, C.; Tun, H. W.; de la Fuente Burguera, A. D.; Dabrowska-Iwanicka, A.; Regales, L.; Zhao, W.; Ferrari, D.; Fowles, M.; Lane, M. E.; Wang, C.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Avutometinib/defactinib and gemcitabine/nab-paclitaxel combination in first-line metastatic pancreatic ductal adenocarcinoma: Initial safety and efficacy of phase 1b/2 study (RAMP 205)

Meeting Abstract

Lim, K. H.; Spencer, K. R.; Safyan, R. A.; Picozzi, V. J.; Varghese, A. M.; Siolas, D.; Perez, K.; Clift, S.; Denis, L. J.; Bhambhani, V.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save